Tolerability and safety of the new anti-obesity medications
Jazyk angličtina Země Nový Zéland Médium print
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
- MeSH
- benzazepiny škodlivé účinky MeSH
- benzoxaziny škodlivé účinky MeSH
- bupropion škodlivé účinky MeSH
- chemie farmaceutická MeSH
- fentermin aplikace a dávkování škodlivé účinky MeSH
- fruktosa aplikace a dávkování škodlivé účinky analogy a deriváty MeSH
- glukagonu podobný peptid 1 škodlivé účinky analogy a deriváty MeSH
- látky proti obezitě aplikace a dávkování škodlivé účinky MeSH
- lidé MeSH
- liraglutid MeSH
- naltrexon škodlivé účinky MeSH
- nežádoucí účinky léčiv MeSH
- obezita farmakoterapie MeSH
- topiramat MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
- Názvy látek
- benzazepiny MeSH
- benzoxaziny MeSH
- bupropion MeSH
- cetilistat MeSH Prohlížeč
- fentermin MeSH
- fruktosa MeSH
- glukagonu podobný peptid 1 MeSH
- látky proti obezitě MeSH
- liraglutid MeSH
- lorcaserin MeSH Prohlížeč
- naltrexon MeSH
- topiramat MeSH
Worldwide obesity prevalence has nearly doubled since 1980. Due to numerous co-morbidities, obesity represents a serious health and socioeconomic problem worldwide. Pharmacotherapy should be an integral part of comprehensive obesity management. Drug therapy can assist in weight loss and its maintenance in those individuals who do not achieve appropriate weight loss through lifestyle interventions alone. After the withdrawal of sibutramine from the market in 2010, orlistat, a lipase inhibitor, was the only remaining prescription drug approved for the long-term treatment of obesity. In 2012, phentermine/topiramate extended-release (PHEN/TPM ER) combination and lorcaserin were approved by the US FDA as novel medications for long-term weight management. Three major phase III trials conducted with each drug confirmed their efficacy in terms of weight loss/maintenance and improvement of cardiometabolic risks. No head-to-head studies between the two new anti-obesity drugs have been carried out. However, in the existing studies PHEN/TPM ER had a superior weight loss profile to lorcaserin but the incidence of adverse effects was lower with lorcaserin. Both drugs were well-tolerated, and adverse events were modest in intensity, dose dependent, rather rare, and tended to decrease with the duration of treatment. Major safety concerns regarding PHEN/TPM ER include elevations in resting pulse rate, teratogenicity, mild metabolic acidosis, and psychiatric and cognitive adverse events. Valvulopathy, cognitive impairment, psychiatric disorders, and hypoglycemia represent major safety concerns for lorcaserin. Although existing trials have not demonstrated any significant issues with PHEN/TPM ER-induced heart rate elevation and lorcaserin-induced valvulopathy, all safety concerns should be seriously taken into account in patients treated with either of these novel anti-obesity medications.
Zobrazit více v PubMed
Obesity (Silver Spring). 2011 Dec;19(12):2351-60 PubMed
Obesity (Silver Spring). 2011 Jan;19(1):110-20 PubMed
Int J Obes (Lond). 2012 Jun;36(6):843-54 PubMed
Int J Obes (Lond). 2007 Mar;31(3):494-9 PubMed
J Hypertens. 2014 Jun;32(6):1178-88 PubMed
Cardiovasc Diabetol. 2013 Sep 06;12:130 PubMed
Expert Rev Cardiovasc Ther. 2010 Dec;8(12):1777-801 PubMed
Lancet. 2010 Aug 21;376(9741):595-605 PubMed
N Engl J Med. 2010 Sep 2;363(10):905-17 PubMed
Eur J Ophthalmol. 2011 Jul-Aug;21(4):404-9 PubMed
Int J Obes (Lond). 2013 Nov;37(11):1443-51 PubMed
Lancet. 2011 Apr 16;377(9774):1341-52 PubMed
Diabetes Care. 2013 Dec;36(12):4022-9 PubMed
N Engl J Med. 2012 Oct 25;367(17):1577-9 PubMed
Sleep. 2012 Nov 01;35(11):1529-39 PubMed
J Clin Endocrinol Metab. 2011 Oct;96(10):3067-77 PubMed
Obesity (Silver Spring). 2014 Mar;22(3):943-9 PubMed
Obesity (Silver Spring). 2010 Jan;18(1):108-15 PubMed
Obes Facts. 2013;6(5):449-68 PubMed
Am J Cardiol. 2013 Apr 15;111(8):1131-8 PubMed
Lancet. 2007 Nov 17;370(9600):1706-13 PubMed
Diabetes Metab Res Rev. 2012 Dec;28 Suppl 2:8-20 PubMed
N Engl J Med. 1997 Aug 28;337(9):602-6 PubMed
Am J Obstet Gynecol. 2012 Nov;207(5):405.e1-7 PubMed
Expert Opin Drug Saf. 2013 Sep;12(5):741-56 PubMed
Diabetes Care. 2007 Feb;30(2):395-402 PubMed
Obes Rev. 2010 Dec;11(12):833-4 PubMed
Am J Clin Nutr. 2012 Feb;95(2):297-308 PubMed
Obesity (Silver Spring). 2012 Feb;20(2):330-42 PubMed
N Engl J Med. 2005 Nov 17;353(20):2111-20 PubMed
Obesity (Silver Spring). 2012 Jul;20(7):1426-36 PubMed
Diabetes Care. 2014 Apr;37(4):912-21 PubMed
Obesity (Silver Spring). 2013 May;21(5):935-43 PubMed
Diabetes Care. 2004 Jan;27(1):155-61 PubMed
Obesity (Silver Spring). 2013 May;21(5):861-4 PubMed
Diabetes Metab Syndr Obes. 2013 Apr 08;6:131-9 PubMed
J Clin Endocrinol Metab. 2011 Mar;96(3):837-45 PubMed
Circ Cardiovasc Imaging. 2013 Jul;6(4):560-7 PubMed
Pharmacotherapy. 2006 Mar;26(3):375-87 PubMed
Diabetes Care. 2008 Feb;31 Suppl 2:S269-77 PubMed
N Engl J Med. 2013 Jul 11;369(2):145-54 PubMed
Obesity (Silver Spring). 2013 Nov;21(11):2163-71 PubMed
Obes Facts. 2008;1(2):106-16 PubMed
Obesity (Silver Spring). 2014 Jan;22(1):5-13 PubMed
Int J Obes Relat Metab Disord. 1992 Jun;16(6):397-415 PubMed
Epilepsia. 1996 Jun;37(6):539-43 PubMed
JAMA. 2000 Apr 5;283(13):1703-9 PubMed
World Health Organ Tech Rep Ser. 2000;894:i-xii, 1-253 PubMed
Int J Obes Relat Metab Disord. 1999 May;23 Suppl 4:S14-8; discussion S18-9 PubMed
Appl Ther. 1963 Jun;5:523-4 PubMed
N Engl J Med. 2010 Jul 15;363(3):245-56 PubMed
